Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about $64,000 a year.
That estimated 2018 price of $64,000 a year exceeds, if slightly, the range previously expected by Wall Street analysts at about $20,000 to $60,000 a year.
